These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35355244)
41. Constructing multiple test procedures for partially ordered hypothesis sets. Edwards D; Madsen J Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650 [TBL] [Abstract][Full Text] [Related]
42. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates. Van Lancker K; Vandebosch A; Vansteelandt S Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662 [TBL] [Abstract][Full Text] [Related]
43. Weighted composite time to event endpoints with recurrent events: comparison of three analytical approaches. Ozga AK; Rauch G BMC Med Res Methodol; 2022 Feb; 22(1):38. PubMed ID: 35123397 [TBL] [Abstract][Full Text] [Related]
44. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning. Schmidt R; Burkhardt B; Faldum A Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500 [TBL] [Abstract][Full Text] [Related]
45. A less conservative method to adjust for familywise error rate in neuropsychological research: the Holm's sequential Bonferroni procedure. Eichstaedt KE; Kovatch K; Maroof DA NeuroRehabilitation; 2013; 32(3):693-6. PubMed ID: 23648625 [TBL] [Abstract][Full Text] [Related]
46. Sample size determination for equivalence assessment with multiple endpoints. Sun A; Dong X; Tsong Y J Biopharm Stat; 2014; 24(6):1203-14. PubMed ID: 25032845 [TBL] [Abstract][Full Text] [Related]
48. Sequential parallel comparison design with two coprimary endpoints. Homma G; Daimon T Pharm Stat; 2020 May; 19(3):243-254. PubMed ID: 31829521 [TBL] [Abstract][Full Text] [Related]
49. On sample size determination in multi-armed confirmatory adaptive designs. Wassmer G J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570 [TBL] [Abstract][Full Text] [Related]
50. Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints. Yang J; Li J; Wang S; Luo L; Liu P Hum Vaccin Immunother; 2019; 15(1):256-263. PubMed ID: 30273507 [TBL] [Abstract][Full Text] [Related]
54. A method for testing a prespecified subgroup in clinical trials. Song Y; Chi GY Stat Med; 2007 Aug; 26(19):3535-49. PubMed ID: 17266164 [TBL] [Abstract][Full Text] [Related]
55. Reliably picking the best endpoint. Follmann D Stat Med; 2018 Dec; 37(29):4374-4385. PubMed ID: 30091264 [TBL] [Abstract][Full Text] [Related]
56. Some controversial multiple testing problems in regulatory applications. Hung HM; Wang SJ J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460 [TBL] [Abstract][Full Text] [Related]
57. The impact of multiple endpoint dependency on Q and I(2) in meta-analysis. Thompson CG; Becker BJ Res Synth Methods; 2014 Sep; 5(3):235-53. PubMed ID: 26052849 [TBL] [Abstract][Full Text] [Related]